Erste Asset Management GmbH Makes New $2.67 Million Investment in Stoke Therapeutics, Inc. $STOK

Key Points

• Erste Asset Management GmbH has acquired 396,000 shares of Stoke Therapeutics, Inc. (NASDAQ:STOK), valued at approximately $2.67 million, representing a 0.73% stake in the company.
• The latest earnings report indicated a loss of ($0.40) EPS, beating expectations, with revenue of $13.82 million, significantly lower than the analyst estimates of $31.51 million.
• Analyst ratings for Stoke Therapeutics are generally positive, with two analysts giving a Strong Buy rating, contributing to an average price target of $25.57 for the stock.

Erste Asset Management GmbH acquired a new stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 396,000 shares of the company's stock, valued at approximately $2,670,000. Erste Asset Management GmbH owned 0.73% of Stoke Therapeutics at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in STOK. Wellington Management Group LLP grew its holdings in shares of Stoke Therapeutics by 0.9% in the first quarter. Wellington Management Group LLP now owns 135,960 shares of the company's stock worth $904,000 after acquiring an additional 1,148 shares during the period. Fox Run Management L.L.C. acquired a new stake in Stoke Therapeutics in the 1st quarter worth about $92,000. Russell Investments Group Ltd. purchased a new stake in Stoke Therapeutics in the first quarter valued at approximately $107,000. Nuveen LLC purchased a new stake in shares of Stoke Therapeutics during the first quarter worth $719,000. Finally, Invesco Ltd. grew its holdings in shares of Stoke Therapeutics by 117.0% during the first quarter. Invesco Ltd. now owns 26,183 shares of the company's stock worth $174,000 after purchasing an additional 14,118 shares during the last quarter.

Stoke Therapeutics Stock Performance

STOK traded up $0.35 during trading on Wednesday, reaching $19.72. 204,804 shares of the company's stock were exchanged, compared to its average volume of 805,540. Stoke Therapeutics, Inc. has a fifty-two week low of $5.35 and a fifty-two week high of $19.97. The firm has a market capitalization of $1.08 billion, a PE ratio of 23.31 and a beta of 1.15. The company's fifty day moving average price is $13.61 and its 200-day moving average price is $10.51.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.57) by $0.17. The business had revenue of $13.82 million for the quarter, compared to analyst estimates of $31.51 million. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%. Research analysts forecast that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

STOK has been the subject of a number of research analyst reports. Cantor Fitzgerald upgraded Stoke Therapeutics to a "strong-buy" rating in a report on Wednesday, May 14th. BTIG Research set a $28.00 price objective on shares of Stoke Therapeutics and gave the stock a "buy" rating in a report on Monday, August 18th. Chardan Capital reaffirmed a "buy" rating and issued a $24.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, August 13th. Wedbush upped their price target on shares of Stoke Therapeutics from $16.00 to $22.00 and gave the company an "outperform" rating in a report on Wednesday, August 13th. Finally, HC Wainwright dropped their price target on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Two research analysts have rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $25.57.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 4,504 shares of the business's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $12.82, for a total value of $57,741.28. Following the completion of the transaction, the insider owned 16,775 shares of the company's stock, valued at $215,055.50. The trade was a 21.17% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Jonathan Allan sold 13,712 shares of the company's stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $15.00, for a total transaction of $205,680.00. Following the completion of the sale, the general counsel directly owned 19,631 shares of the company's stock, valued at $294,465. This trade represents a 41.12% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 26,432 shares of company stock valued at $345,775. Insiders own 9.50% of the company's stock.

Stoke Therapeutics Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.